Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

W. Flinn, Ian; van der Jagt, Richard; S. Kahl, Brad; Wood, Peter; E. Hawkins, Tim; MacDonald, David; Hertzberg, Mark; Kwan, Yiu-Lam; Simpson, David; Craig, Michael; Kolibaba, Kathryn; Issa, Samar; Clementi, Regina; M. Hallman, Doreen; Munteanu, Mihaela; Chen, Ling; M. Burke, John

doi:10.1182/blood-2013-11-531327

Public

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Shared by NobleBlocks on May 8, 2014 • 12:00 AM UTC

Authors:

Ian W. Flinn

Richard van der Jagt

Brad S. Kahl

Abstract

Key Points The complete response rate for first-line bendamustine/rituximab was statistically noninferior to R-CHOP or R-CVP in indolent NHL or MCL. The safety profile of bendamustine/rituximab is distinct from that of R-CHOP/R-CVP.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!